

Table (7): Outcome of the whole study population.

Outcome	All patients
Count (%)	150 (100%)
Outcome	
No failure	30 (20%)
Local recurrence alone	26 (17.3%)
Locoregional recurrence	16 (10.7%)
Distant metastasis	78 (52%)
DM Alone	48 (61.5%)
DM with Local recurrence	21 (26.9%)
DM with Loco-regional recurrence	9 (11.6%)
Site of metastasis	
Liver	9 (6%)
Bone	50 (33.3%)
Lung	7 (5.3%)
Brain	3 (2%)
multiple organ	9(6%)

Table (8): Comparison between patients who developed local recurrence and those who didn't regarding the tumor staging.

Tumor staging	Local recurrence	No local recurrence	Test	P-value (Sig.)
Count	26	124		
N. of positive LNs				
Median (IQR)	8 (2 – 14)	12 (1 – 20)	-1.502 •	0.133(NS)
Tumor size (cm)				
Median (IQR)	4 (2.5 – 8)	3 (3 – 6)	0.516 •	0.606(NS)
T system				
T2	2 (7.8%)	38 (30.8%)	8.65	0.013* (S)
T3	8 (30.7%)	44 (35.4%)		
T4	16 (61.5%)	42 (33.8%)		
N system				
N1	2 (7.8%)	10 (8.2%)	0.97	0.81 (NS)
N2	10 (38.4%)	49 (39.5%)		
N3	14 (53.8%)	65 (52.3%)		
Stage				
Stage IIIA	13 (50%)	31 (25%)	5.758 ‡	0.016* (S)
Stage IIIB	4 (15.4%)	25 (20.2%)		
Stage IIIC	9 (34.6%)	68 (54.8%)		
Receptors				
ER	22 (84.6%)	91 (73.4%)	1.458 ‡	0.227(NS)
PR	21 (80.8%)	86 (69.4%)	1.369 ‡	0.242(NS)
HER2/neu +VE	10 (38.5%)	53 (42.7%)	0.162 ‡	0.688(NS)

* Independent samples Student's t-test. • Mann Whitney U test. ‡ Chi-square test. ‡ Linear-by-linear association. p < 0.05 is significant. Sig.: significance.

Table (9): Comparison between patients who developed locoregional recurrence and those who didn't regarding the tumor staging.

Tumor staging	Locoregional recurrence	No locoregional recurrence	Test	P-value (Sig.)
Count	16	134		
N. of positive LNs				
Median (IQR)	10.5 (2 – 13.5)	12 (1 – 20)	-0.351 •	0.726(NS)
Tumor size (cm)				
Median (IQR)	5 (3 – 10)	3 (3 – 6)	1.450 •	0.180(NS)
T system				
T1	0 (0.0%)	0 (0.0%)	8.61 ‡ ^F	0.018*(S)
T2	1 (6.3%)	40 (29.8%)		
T3	3 (18.8%)	48 (35.8%)		
T4	12 (75.0%)	46 (34.3%)		
N system				
N1	3 (18.8%)	9 (6.7%)	4.84 ‡ ^F	0.08(NS)
N2	3 (18.8%)	56 (45.1%)		
N3	10 (62.4%)	69 (48.2%)		
Stage				
Stage IIIA	0 (18.8%)	44 (30.6%)	10.49 ‡ ^F	0.005*(S)
Stage IIIB	1 (18.8%)	28 (19.4%)		
Stage IIIC	15 (93.8%)	62 (50.0%)		
Receptors				
ER	15 (93.8%)	98 (73.1%)	2.41 ‡	0.120(NS)
PR	10 (62.4%)	65 (48.5%)	1.44 ‡	0.21(NS)
HER2/neu +VE	8 (50%)	55 (41%)	0.471 ‡	0.493(NS)

* Independent samples Student's t-test. • Mann Whitney U test. ‡ Chi-square test. ‡ Linear-by-linear association. ‡^F Fisher's Exact test. p< 0.05 is significant. Sig.: significance.

Table (10): Comparison between patients who developed distant metastasis and those who didn't regarding the tumor staging.

Tumor staging	Distant metastasis	No distant metastasis	Test	P-value (Sig.)
Count	78	72		
N. of positive LNs				
Median (IQR)	14 (4 – 20)	12 (1 – 16)	1.057 •	0.290(NS)
Tumor size (cm)				
Median (IQR)	4.5 (3 – 6.5)	4 (3 – 5)	1.170 •	0.242(NS)
T system				
T2	21 (26.9%)	19 (26.2%)	0.162	0.911 (NS)
T3	28 (35.8%)	24 (33.3%)		
T4	29 (40.3%)	29 (40.5%)		
N system				
N1	0 (0.0%)	12 (11.1%)	54.21	0.00** (HS)
N2	15 (19.2%)	44 (61.1 %)		
N3	63 (80.8%)	16 (22.2%)		
Stage				
Stage IIIA	16 (20.6%)	28 (38.8%)	6.321 ‡	0.041*(S)
Stage IIIB	18 (23.1%)	11 (15.2%)		
Stage IIIC	44 (56.3%)	33 (45.8%)		
Receptors				
ER	59 (75.6%)	54 (75%)	0.008 ‡	0.928(NS)
PR	55 (70.5%)	52 (72.2%)	0.054 ‡	0.817(NS)
HER2/neu +VE	31 (39.7%)	32 (44.4%)	0.340 ‡	0.560(NS)

* Independent samples Student's t-test. • Mann Whitney U test. ‡ Chi-square test. ‡ Linear-by-linear association. p< 0.05 is significant. Sig.: significance.